• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Y1206S突变增加了磺脲类受体SUR2A对格列本脲的亲和力,并增强了与Kir6.2共表达的效果。

The mutation Y1206S increases the affinity of the sulphonylurea receptor SUR2A for glibenclamide and enhances the effects of coexpression with Kir6.2.

作者信息

Stephan Damian, Stauss Eva, Lange Ulf, Felsch Holger, Löffler-Walz Cornelia, Hambrock Annette, Russ Ulrich, Quast Ulrich

机构信息

Department of Pharmacology and Toxicology, Medical Faculty, Pharmakologisches Institut/Abt. Molekularpharmakologie, University of Tübingen, Wilhelmstr. 56, Tübingen, D-72074 Germany.

出版信息

Br J Pharmacol. 2005 Apr;144(8):1078-88. doi: 10.1038/sj.bjp.0706142.

DOI:10.1038/sj.bjp.0706142
PMID:15711591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1576091/
Abstract
  1. ATP-sensitive K(+) channels (K(ATP) channels) are tetradimeric complexes of inwardly rectifying K(+) channels (Kir6.x) and sulphonylurea receptors (SURs). The SURs SUR2A (cardiac) and SUR2B (smooth muscle) differ only in the last 42 amino acids. In SUR2B, the mutation Y1206S, located at intracellular loop 8, increases the affinity for glibenclamide (GBC) about 10-fold. Here, we examined whether the mutation Y1206S in SUR2A had effects similar to those in SUR2B.2. GBC bound to SUR2A with K(D)=20 nM; the mutation increased affinity approximately 5 x. 3. In cells, coexpression of SUR2A with Kir6.2 increased the affinity for GBC approximately 3 x; with the mutant, the increase was 9 x. 4. The mutation did not affect the affinity of SUR2A for openers; coexpression with Kir6.2 reduced opener affinity of wild-type and mutant SUR2A by about 2 x. 5. The negative allosteric interaction between the opener, P1075, and GBC at wild-type and mutant SUR2A was markedly affected by the presence of MgATP and by coexpression with Kir6.2. 6. In inside-out patches, GBC inhibited the wild-type Kir6.2/SUR2A and 2B channels with IC(50) values of 27 nM; the mutation shifted the IC(50) values to approximately 1 nM. 7. The data show that the mutation Y1206S increased the affinity of SUR2A for GBC and modulated the effects of coexpression. Overall, the changes were similar to those observed with SUR2B(Y1206S), suggesting that the differences in the last 42 carboxy-terminal amino acids of SUR2A and 2B are of limited influence on the binding of GBC and P1075 to the SUR2 isoforms.
摘要
  1. ATP敏感性钾通道(K(ATP)通道)是内向整流钾通道(Kir6.x)和磺脲类受体(SURs)的四聚体复合物。SURs中的SUR2A(心脏型)和SUR2B(平滑肌型)仅在最后42个氨基酸上有所不同。在SUR2B中,位于细胞内环8的Y1206S突变使对格列本脲(GBC)的亲和力增加约10倍。在此,我们研究了SUR2A中的Y1206S突变是否具有与SUR2B中类似的效应。

  2. GBC与SUR2A结合的解离常数K(D)=20 nM;该突变使亲和力增加约5倍。

  3. 在细胞中,SUR2A与Kir6.2共表达使对GBC的亲和力增加约3倍;对于突变体,增加了9倍。

  4. 该突变不影响SUR2A对开放剂的亲和力;与Kir6.2共表达使野生型和突变型SUR2A的开放剂亲和力降低约2倍。

  5. 开放剂P1075与GBC在野生型和突变型SUR2A上的负变构相互作用受到MgATP的存在以及与Kir6.2共表达的显著影响。

  6. 在外翻式膜片中,GBC抑制野生型Kir6.2/SUR2A和2B通道的半数抑制浓度IC(50)值为27 nM;该突变使IC(50)值约为1 nM。

  7. 数据表明,Y1206S突变增加了SUR2A对GBC的亲和力并调节了共表达的效应。总体而言,这些变化与SUR2B(Y1206S)中观察到的相似,表明SUR2A和2B最后42个羧基末端氨基酸的差异对GBC和P1075与SUR2亚型的结合影响有限。

相似文献

1
The mutation Y1206S increases the affinity of the sulphonylurea receptor SUR2A for glibenclamide and enhances the effects of coexpression with Kir6.2.Y1206S突变增加了磺脲类受体SUR2A对格列本脲的亲和力,并增强了与Kir6.2共表达的效果。
Br J Pharmacol. 2005 Apr;144(8):1078-88. doi: 10.1038/sj.bjp.0706142.
2
Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6.x subtypes.对磺脲类药物和开放剂具有高亲和力的突变型磺脲类受体SUR2B的特性:与Kir6.x亚型偶联的差异。
Mol Pharmacol. 2001 Jul;60(1):190-9. doi: 10.1124/mol.60.1.190.
3
Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides.格列本脲与磺酰脲受体亚型的结合:对腺嘌呤核苷酸的依赖性。
Br J Pharmacol. 2002 Aug;136(7):995-1004. doi: 10.1038/sj.bjp.0704801.
4
Lipids modulate ligand binding to sulphonylurea receptors.脂质调节配体与磺酰脲受体的结合。
Br J Pharmacol. 2005 Aug;145(7):907-15. doi: 10.1038/sj.bjp.0706252.
5
Coexpression with the inward rectifier K(+) channel Kir6.1 increases the affinity of the vascular sulfonylurea receptor SUR2B for glibenclamide.与内向整流钾离子通道Kir6.1共表达可增加血管磺脲类受体SUR2B对格列本脲的亲和力。
Mol Pharmacol. 1999 Nov;56(5):955-61.
6
Interaction of a novel dihydropyridine K+ channel opener, A-312110, with recombinant sulphonylurea receptors and KATP channels: comparison with the cyanoguanidine P1075.新型二氢吡啶钾通道开放剂A-312110与重组磺酰脲受体及KATP通道的相互作用:与氰基胍P1075的比较
Br J Pharmacol. 2004 Apr;141(7):1098-105. doi: 10.1038/sj.bjp.0705718. Epub 2004 Mar 15.
7
Interaction of K(ATP) channel modulators with sulfonylurea receptor SUR2B: implication for tetramer formation and allosteric coupling of subunits.K(ATP)通道调节剂与磺脲类受体SUR2B的相互作用:对四聚体形成及亚基变构偶联的影响
Mol Pharmacol. 2002 Feb;61(2):407-14. doi: 10.1124/mol.61.2.407.
8
Potassium channel openers require ATP to bind to and act through sulfonylurea receptors.钾通道开放剂需要ATP与磺脲类受体结合并通过该受体起作用。
EMBO J. 1998 Oct 1;17(19):5529-35. doi: 10.1093/emboj/17.19.5529.
9
Substitution of the Walker A lysine by arginine in the nucleotide-binding domains of sulphonylurea receptor SUR2B: effects on ligand binding and channel activity.苏氨酸受体 SUR2B 核苷酸结合域中 Walker A 赖氨酸被精氨酸取代:对配体结合和通道活性的影响。
Naunyn Schmiedebergs Arch Pharmacol. 2010 Jun;381(6):507-16. doi: 10.1007/s00210-010-0510-0. Epub 2010 Mar 30.
10
ATP-Sensitive K+ channel modulator binding to sulfonylurea receptors SUR2A and SUR2B: opposite effects of MgADP.ATP敏感性钾通道调节剂与磺脲类受体SUR2A和SUR2B的结合:MgADP的相反作用
Mol Pharmacol. 1999 May;55(5):832-40.

引用本文的文献

1
Substitution of the Walker A lysine by arginine in the nucleotide-binding domains of sulphonylurea receptor SUR2B: effects on ligand binding and channel activity.苏氨酸受体 SUR2B 核苷酸结合域中 Walker A 赖氨酸被精氨酸取代:对配体结合和通道活性的影响。
Naunyn Schmiedebergs Arch Pharmacol. 2010 Jun;381(6):507-16. doi: 10.1007/s00210-010-0510-0. Epub 2010 Mar 30.
2
Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels.瑞格列奈和格列本脲对胰腺K(ATP)通道相对于心血管K(ATP)通道的选择性。
Diabetologia. 2006 Sep;49(9):2039-48. doi: 10.1007/s00125-006-0307-3. Epub 2006 Jul 25.
3
Lipids modulate ligand binding to sulphonylurea receptors.脂质调节配体与磺酰脲受体的结合。
Br J Pharmacol. 2005 Aug;145(7):907-15. doi: 10.1038/sj.bjp.0706252.

本文引用的文献

1
Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.Kir6.2依赖性高亲和力瑞格列奈与β细胞K(ATP)通道的结合
Br J Pharmacol. 2005 Feb;144(4):551-7. doi: 10.1038/sj.bjp.0706082.
2
Interaction of a novel dihydropyridine K+ channel opener, A-312110, with recombinant sulphonylurea receptors and KATP channels: comparison with the cyanoguanidine P1075.新型二氢吡啶钾通道开放剂A-312110与重组磺酰脲受体及KATP通道的相互作用:与氰基胍P1075的比较
Br J Pharmacol. 2004 Apr;141(7):1098-105. doi: 10.1038/sj.bjp.0705718. Epub 2004 Mar 15.
3
Protein measurement with the Folin phenol reagent.使用福林酚试剂进行蛋白质测定。
J Biol Chem. 1951 Nov;193(1):265-75.
4
Assembly, maturation, and turnover of K(ATP) channel subunits.K(ATP) 通道亚基的组装、成熟与更新
J Biol Chem. 2004 Mar 5;279(10):9080-90. doi: 10.1074/jbc.M311079200. Epub 2003 Dec 29.
5
Sulphonylurea action revisited: the post-cloning era.磺脲类药物作用再探讨:克隆时代之后
Diabetologia. 2003 Jul;46(7):875-91. doi: 10.1007/s00125-003-1143-3. Epub 2003 Jun 18.
6
Binding and effect of K ATP channel openers in the absence of Mg2+.在无镁离子情况下钾离子通道开放剂的结合与作用
Br J Pharmacol. 2003 May;139(2):368-80. doi: 10.1038/sj.bjp.0705238.
7
Physiological and pathophysiological roles of ATP-sensitive K+ channels.ATP敏感性钾通道的生理和病理生理作用。
Prog Biophys Mol Biol. 2003 Feb;81(2):133-76. doi: 10.1016/s0079-6107(02)00053-6.
8
Sulfonylurea stimulation of insulin secretion.磺脲类药物对胰岛素分泌的刺激作用。
Diabetes. 2002 Dec;51 Suppl 3:S368-76. doi: 10.2337/diabetes.51.2007.s368.
9
Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides.格列本脲与磺酰脲受体亚型的结合:对腺嘌呤核苷酸的依赖性。
Br J Pharmacol. 2002 Aug;136(7):995-1004. doi: 10.1038/sj.bjp.0704801.
10
Four novel splice variants of sulfonylurea receptor 1.磺脲类受体1的四种新型剪接变体。
Am J Physiol Cell Physiol. 2002 Aug;283(2):C587-98. doi: 10.1152/ajpcell.00083.2002.